Results 171 to 180 of about 21,604,258 (289)
Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Chimeric antigen receptor (CAR) T cell therapy is a novel and innovative immunotherapy. CAR-T cells are genetically engineered T cells, carrying MHC independent specific antigen receptor and co-stimulatory molecule which can activate an immune response ...
Arora, Ena, MD +2 more
core
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley +1 more source
Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy. [PDF]
Naser A, Morgan AA, Zhang L.
europepmc +1 more source
This review details a three‐stage paradigm shift for tumor‐reactive CD8+ T‐cell identification: decoding transcriptomic states, deciphering clonal functional efficacy, and molecular‐level therapeutic TCR design. Addressing translational hurdles and generative AI “scientific blind spots”—such as missing catch bonds—we present a visionary roadmap.
Chao Yang +4 more
wiley +1 more source
Real-world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T-cell therapy. [PDF]
Hollnberger J +11 more
europepmc +1 more source
Organoid Coculture Models for Cancer Research and Immunotherapy
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang +9 more
wiley +1 more source
The dilemma after chimeric antigen receptor T-cell therapy - to transplant or not? [PDF]
Jacoby E, Bielorai B.
europepmc +1 more source
ABSTRACT Targeted elimination of pathogenic proteins remains a fundamental challenge in therapeutic intervention, particularly for proteins considered “undruggable” by conventional inhibition‐based approaches. Aptamer–based targeted protein degradation (TPD) has emerged as a versatile strategy that leverages the high specificity, structural ...
Ambrin Malik +3 more
wiley +1 more source
Chimeric antigen receptor T-cell therapy in neuroimmune diseases: mechanistic rationale, clinical experience, and translational challenges. [PDF]
Yi Y +9 more
europepmc +1 more source
SHP2 in Cancer: From Tumor Biology to Therapeutic Targeting
ABSTRACT SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA repair, angiogenesis ...
Maryam Jama +2 more
wiley +1 more source

